Moderna, Inc. amended its existing credit agreement with Ares Capital Corporation, the company said in a filing with the SEC.
The amendment, dated November 9, 2026, modifies the original Credit and Guaranty Agreement that Moderna entered into on November 19, 2025 with Ares Capital Corporation serving as Administrative Agent and Collateral Agent.
Under the changes, the Applicable Margin on the Initial Term Loans is modified and the Term Loan Maturity Date for those loans is extended. The Delayed Draw Termination Date applicable to the Delayed Draw Term Loan-1 and Delayed Draw Term Loan-2 Commitments is also extended. The agreement notes that other amendments and modifications were made as well.
The amendment became effective once a series of conditions were satisfied, including delivery of signed counterparts from Moderna and the lenders constituting all lenders under the existing agreement, an officer's certificate, a good standing certificate, and a legal opinion from Goodwin Procter LLP, special counsel to Moderna and its guarantor subsidiaries. The administrative agent also required a solvency certificate from Moderna's chief financial officer or an officer with equivalent duties, certifying the solvency of the company and its subsidiaries on a consolidated basis after the amendment takes effect.
Moderna was required to pay all accrued and unpaid interest on outstanding loans and all accrued and unpaid commitment fees related to the Delayed Draw Term Loan Commitments as of the effective date, along with outstanding costs and expenses owed to the administrative agent and lenders.
The filing states that the amendment does not extinguish payment obligations outstanding under the credit agreement or discharge any related security or guarantees, and does not constitute a novation. Except as modified, the existing credit agreement and related credit documents remain in full force and effect, and Moderna reaffirmed its obligations and guarantees under those documents.
